Australian Medtech Companies Seizing Opportunities at the Texas Medical Center
12 Sep 2018
Applications open for Texas Medical Center Accelerator Program
Australian digital health companies, this one is for you. Get the inside running on the US market and apply for the next Texas Medical Center Accelerator Program (TMCx). Applications are open until 21 October and successful applicants will travel to Houston for a February 2019 start.
TMCx provides participating companies with access to a network of over 250 expert advisers from the 21 Texas Medical Center hospitals, as well as a tailored curriculum to clinically validate participants' products and establish US market-fit for their solutions. Immersion in this ecosystem provides broad exposure to industry, with the program culminating in TMCx Demo Day: a presentation to hundreds of investors, corporate partners, hospital stakeholders and media.
TMCx guides two cohorts of companies per year – one focused on digital health and the other on medical devices. Seven Australian companies have participated so far, including CNS Dose (digital health cohort 2017), which was one of the first recipients of funding from the TMC Venture Fund. Personify Care (digital health cohort 2017) has leveraged networks made through the TMCx program and established a permanent presence in Houston with two employees, and is currently seeking US customers.
Australian medtech companies De Motu Cordis and Airway Medical Innovations are presently immersed in TMCx. Airway Medical Innovations is focused on commercialising technology to manage the medical airway. Its new laryngoscope facilitates endotracheal intubation, a high-risk medical procedure only performed by medical professionals and paramedics. The company’s vision is to make this critical procedure safer, quicker and easier.
Julio Alonso, Director of Airway Medical Innovations, said: ‘The TMCx Accelerator has been fantastic so far. It is a great opportunity for Australian startups to learn and share with other startup teams from all over the world.
‘The Houston ecosystem is ideal for startups to grow and scale. TMCx is a place that inspires and makes work and random connections easy and enjoyable. The opportunities for clinical connections and development are huge and we plan to leverage this opportunity to hopefully launch in the US market soon.’
De Motu Cordis has developed a product to treat anaphylaxis – the first non-invasive product for the rapid delivery of adrenaline. De Motu Cordis Chief Operating Officer Tamara Mills said people are reluctant to use an EpiPen in emergency and critical care situations.
‘De Motu Cordis is commercialising a product that is kid-friendly and needle-free – call it a “smart inhaler”. Our device is simple enough that a mum or dad can use it in the street. Its simplicity is its brilliance. It allows us to give adrenaline within 2-4 minutes, improving blood flow to the brain and the patient’s quality of life.”
Mills said participation in TMCx will allow the company to accelerate US market access for its product.
The participation of De Motu Cordis and Airway Medical Innovations in the four-month TMCx placement is through the Austrade-designed Bio-Bridge Initiative, a health technology exchange between Australia and the Texas Medical Center. This program is offered at no participation cost to successful companies and TMC does not retain equity.
Apply to TMCx or contact Emma Aitken, Investment Director at Austrade Houston, for more information.